Amneal Pharmaceuticals (NYSE: AMRX)
Some price data may be temporarily unavailable.
Amneal Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Amneal Pharmaceuticals Company Info
Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generic, Specialty and AvKARE Segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The AvKARE segment focuses on pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.
News & Analysis
Why Shares of Amneal Pharmaceuticals Are Plunging Wednesday
The company received a complete response letter from the FDA regarding a Parkinson's disease generic therapy.
Top Drug Stocks Under $5
Healthcare bargain hunters can find good values in quality low-priced stocks.
Amneal Ramping Up Malaria Drug Production to Treat Coronavirus Patients
The company expects to produce around 20 million tablets within a month.
Are Chloroquine and Hydrochloroquine Approved to Treat COVID-19?
No, but doctors can still use the drugs despite limited evidence of their effectiveness.
Valisure Challenges FDA's Claims on Metformin's Safety
The online pharmacy conducted its own tests of the type-2 diabetes drug and found excessive levels of a carcinogenic compound in 42% of the batches it tested.
Here's Why Amneal Pharmaceuticals Rose as Much as 52.3% Today
The generic drug company announced the approval and launch of an important new product.
Why Micro Focus International, MSC Industrial Direct, and Amneal Pharmaceuticals Slumped Today
Company-specific bad news kept these stocks out of the rally.
Here's Why Amneal Pharmaceuticals Fell as Much as 36.6% Today
Stubborn headwinds in the generic drug markets are forcing the company to restructure operations.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.